Tyme Technologies, Inc. (TYME)
Stock Price:
$1.01 USD
-0.02 (-1.94%)
Updated November 27, 1:00 PM EST - Market closed
Key Info
| Market Cap |
131.47M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-28.36M |
| Shares Out |
130.17M |
| EPS (ttm) |
-0.23 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$1.01 |
| Previous Close |
$1.03 |
| Change ($) |
-0.02 |
| Change (%) |
-1.94% |
| Day's Open |
1.04 |
| Day's Range |
1.01 - 1.04 |
| Day's Volume |
180,800 |
| 52-Week Range |
0.85 - 2.04 |
More Stats
| Market Cap |
131.47M |
| Enterprise Value |
112.27M |
| Earnings Date (est) |
Feb 10, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
130.17M |
| Float |
60.72M |
| EPS (basic) |
-0.22 |
| EPS (diluted) |
-0.23 |
| FCF / Share |
-0.18 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.42M |
| Short Ratio |
13.46 |
| Short % of Float |
5.64% |
| Beta |
0.77 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
9.25 |
| Revenue |
n/a |
| Operating Income |
-28.43M |
| Net Income |
-28.36M |
| Free Cash Flow |
-22.76M |
| Net Cash |
19.20M |
| Net Cash / Share |
0.15 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-89.55% |
| ROE |
-260.08% |
| ROIC |
1,061.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$8.75*
(766.34% upside)
Low
8.00
Current: $1.01
High
9.50
Target: 8.75
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Operating Income | -25.76 | -31.78 | -19.36 | -15.21 | -8.60 | -2.58 | -0.06 | -0.03 | - |
| Net Income | -22.00 | -32.98 | -18.97 | -15.21 | -11.73 | -2.65 | -0.06 | -0.03 | - |
| Shares Outstanding | 115 | 102 | 90.57 | 84.45 | 77.85 | 68.00 | 52.00 | 47.60 | 39.00 |
| Earnings Per Share | -0.19 | -0.32 | -0.21 | -0.18 | -0.15 | -0.04 | - | - | - |
| Operating Cash Flow | -19.56 | -20.12 | -11.88 | -5.86 | -6.61 | -1.52 | -0.05 | -0.03 | - |
| Capital Expenditures | - | -0.02 | - | - | - | - | - | - | - |
| Free Cash Flow | -19.56 | -20.13 | -11.88 | -5.86 | -6.61 | -1.52 | -0.05 | -0.03 | - |
| Cash & Equivalents | 26.70 | 14.30 | 28.98 | 10.48 | 4.45 | 0.01 | - | 0.02 | 0.01 |
| Total Debt | 0.57 | 0.60 | 0.48 | - | - | 1.35 | - | - | - |
| Net Cash / Debt | 26.13 | 13.70 | 28.50 | 10.48 | 4.45 | -1.34 | - | 0.02 | 0.01 |
| Assets | 29.50 | 17.52 | 31.02 | 10.72 | 4.49 | 0.17 | - | 0.02 | 0.01 |
| Liabilities | 10.48 | 7.85 | 4.55 | 3.33 | 1.47 | 2.64 | 0.04 | - | - |
| Book Value | 19.03 | 9.67 | 26.47 | 7.39 | 3.02 | -2.47 | -0.04 | 0.01 | 0.01 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Tyme Technologies, Inc. |
| Country |
United States |
| Employees |
18 |
| CEO |
Steve Hoffman |
Stock Information
| Ticker Symbol |
TYME |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: TYME |
Description
Tyme Technologies, a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-18, a CMBT compound that is in preclinical stage for the treatment of solid tumors. Tyme Technologies, Inc. has a research collaboration with NYU Langone Health to advance the development of treatments for patients with metastatic cancers, including pancreatic cancer, as well as with Mayo Clinic; and a strategic collaboration with Eagle Pharmaceuticals, Inc. to advance oral SM-88 for the treatment of patients with cancer. The company was formerly known as Global Group Enterprises Corp. Tyme Technologies, Inc. was founded in 2011 and is headquartered in New York, New York.